Table 2.

Bypass efficacy in patients with aspirin or non-aspirin therapy.

Outcome	Non-aspirin (n = 71)	Aspirin (n = 133)	Z	P
Follow-up mRS, n (%)			−2.275	0.023
0–1	51 (71.8)	114 (85.7)
2–3	18 (25.4)	14 (10.5)
4–5	2 (2.8)	5 (3.8)
Follow-up staging of cerebral perfusion, n (%)			−0.316	0.752
I	12 (16.9)	29 (21.8)
II	28 (39.4)	47 (35.3)
III	21 (29.6)	36 (27.1)
IV	10 (14.1)	21 (15.8)
Follow-up improvement rate of cerebral perfusion, n (%)			−1.201	0.230
Improve	48 (67.6)	102 (76.7)
No Change	17 (23.9)	18 (13.5)
Deteriorate	6 (8.5)	13 (9.8)
Follow-up Matsushima stage, n (%)			−1.365	0.172
A	11 (15.5)	20 (15.0)
B	29 (40.8)	72 (54.1)
C	31 (43.7)	41 (30.8)
Bypass patency, n (%)			−0.928	0.335
Yes	59 (83.1)	117 (88.0)
No	12 (16.9)	16 (12.0)